NYSE:LLY - Eli Lilly And Co Stock Price, Price Target & More

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly And Co declared a quarterly dividend on Monday, June 18th. Shareholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share on Monday, September 10th. This represents a $2.25 dividend on an annualized basis and a yield of 2.59%. View Eli Lilly And Co's Dividend History.

Eli Lilly And Co (NYSE:LLY) issued its quarterly earnings results on Tuesday, April, 24th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.21. The company earned $5.70 billion during the quarter, compared to the consensus estimate of $5.51 billion. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. The business's revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $0.98 EPS. View Eli Lilly And Co's Earnings History.

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly And Co.

Eli Lilly And Co updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

19 equities research analysts have issued 1 year price targets for Eli Lilly And Co's stock. Their forecasts range from $78.00 to $115.00. On average, they anticipate Eli Lilly And Co's share price to reach $93.9444 in the next twelve months. View Analyst Ratings for Eli Lilly And Co.

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

News coverage about LLY stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eli Lilly And Co earned a daily sentiment score of 0.18 on Accern's scale. They also gave press coverage about the company an impact score of 46.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Eli Lilly And Co's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Franklin Resources Inc. (3.00%), Northern Trust Corp (1.04%), Massachusetts Financial Services Co. MA (0.73%), Legal & General Group Plc (0.43%) and Schroder Investment Management Group (0.43%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

LLY stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Neuberger Berman Group LLC, Amundi Pioneer Asset Management Inc., Sei Investments Co., Northern Trust Corp, Massachusetts Financial Services Co. MA, Swiss National Bank and Eaton Vance Management. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.

LLY stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Schroder Investment Management Group, BlackRock Inc., LSV Asset Management, Alps Advisors Inc., Mackay Shields LLC, Point72 Asset Management L.P. and Summit Trail Advisors LLC. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LLY stock can currently be purchased for approximately $86.75.

Eli Lilly And Co has a market capitalization of $94.30 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]